Sajid Ali, MD
Cardiovascular Disease · Houston, TXNPI 1750693248
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (57.1%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by Abbott at 42.5% of the total. Reporting peaked in 2019 at $7,773 and has fallen 78.7% since, to $1,657 in 2025. Among cardiovascular disease clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 618 payments — averaging $58.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$15K
- Cardinal Health 200 LLC$4K
- Medtronic$2K
- Cardiovascular Systems Inc.$1K
- Boston Scientific$1K
- Philips North America LLC$1K
- plus $11K from 54 others
Across 1 payment — averaging $11,166 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$11K
What the payments were for
- Consulting fees$7,16320%
- Speaking & faculty fees$4,50012%
- Travel & lodging$3,69710%
- Food & beverage$20,60257%
- Education$950%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COROFLOW$7,732
- Confirm Rx$1,628
- Xience V coronary stent system$1,556
- Diamondback Peripheral$1,268
- IGT D Peripheral$878
- VenaSeal$736
- Impella$419
- Resolute$392
- Quartet CRT Lead$387
- ADVISOR$311
- OPTIMIZER$304
- XARELTO$266
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$263
- Xience Sierra Coronary Stent$258
- JARDIANCE$238
- QUARTET$231
- ONYX FRONTIER$160
- Angio-Seal Vascular Closure Dev$160
- Merlin Connectivity and Remote$157
- AMPLATZER Occluders$157
How this compares
$36,056 in reported general payments places this provider in the 90th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 177 | $175,027 |
| FarxigaDapagliflozin Propanediol | 133 | $135,131 |
| EntrestoSacubitril/Valsartan | 100 | $121,202 |
| OzempicSemaglutide | 107 | $115,896 |
| EliquisApixaban | 68 | $80,974 |
| BrilintaTicagrelor | 57 | $57,354 |
| JardianceEmpagliflozin | 29 | $40,154 |
| Repatha SyringeEvolocumab | 17 | $13,725 |
| NexlizetBempedoic Acid/Ezetimibe | 12 | $10,954 |
| Wixela InhubFluticasone Propion/Salmeterol | 52 | $5,550 |
| Ranolazine ErRanolazine | 48 | $3,839 |
| Amiodarone Hcl | 56 | $3,822 |
| Nebivolol Hcl | 37 | $3,127 |
| Metoprolol Succinate | 299 | $3,009 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 24 | $2,636 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Brilinta | $371 | $192,485190 claims |
| Johnson & JohnsonXarelto | $1,008 | $175,027177 claims |
| NovartisEntresto | $854 | $121,202100 claims |
| Novo NordiskOzempic | $291 | $115,896107 claims |
| PfizerEliquis | $72 | $80,97468 claims |
| Boehringer IngelheimJardiance | $673 | $40,15429 claims |
| Esperion Therapeutics, Inc.Nexlizet | $203 | $10,95412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in Houston
- Biykem BozkurtHouston$606K
- Reynolds DelgadoHouston$471K
- Christie BallantyneHouston$413K
- Asif AliHouston$411K
- Sanjay ManiarHouston$263K
- Joggy GeorgeHouston$231K
- Jerry EstepHouston$226K
- Stephen LittleHouston$144K
- Akira NishikawaHouston$109K
- Andres MesaHouston$103K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.